

# Management and Control of Childhood Pneumonia: New Perspectives of An Old-fashion Scourge

Octavio Ramilo



NATIONWIDE CHILDREN'S  
*When your child needs a hospital, everything matters.*<sup>TM</sup>



THE OHIO STATE UNIVERSITY  
COLLEGE OF MEDICINE


# Outline

- Importance of pneumonia
- Etiologic agents
- Diagnostic challenges in pediatric pneumonia
- Virus-bacterial interactions
- Interventions in pediatric pneumonia
- New technologies to understand pneumonia

# Is Pneumonia a Major Global Health Care Problem in 2019?

# Pneumonia single most common cause of death

2013 Causes of Death in Children 0-59 mo.






**world  
pneumonia  
day**

**November 12, 2019**

# Pneumonia in Children

- Major advances with implementation of vaccination programs in the last decade
- But pneumonia remains major cause of mortality in children under 5 yrs of age, especially in low resource regions
- Mortality in middle and developed countries is lower
- In those countries pneumonia remains one of most frequent reasons for hospitalization in children
- Diagnostic strategies and treatment guidelines suboptimal

# Traditional approach for diagnosis of lower respiratory tract infections



# Etiologic Diagnosis

# Community acquired pneumonia: Lung tap studies

	N	Positive	<i>S. pneumo</i>	<i>H. influ</i>	<i>S. aureus</i>
		N (%)	%	%	%
Europe	255	168 (66)	40	21	13
USA	645	204 (32)	31	2	5
Africa	1000	659 (66)	17	12	20
Asia	674	343 (51)	10	5	24
Oceania	101	59 (58)	34	42	1

# Bacteriology of Community-acquired pneumonia

	N	Blood+ %	<i>S. pne</i> %	<i>M. pne</i> %	<i>H. inf</i> %	<i>M. cat</i> %	<i>C. pne</i> %	Total %
Ausina et al, 1998	198		15	40	2			58
Claesson et al, 1989	336	1	13	10	1			23
Ruuskanen et al, 1992	50	0	38	20	12	0		62
Block et al, 1995				27			28	
Gendrel et al, 1997	104	8	13	41				55
Harris et al, 1998				30			15	
Heiskanen et al, 1998	201		28	22	6	3		51
Wubbel et al, 1999	168	0	21	7				28
Juvén et al, 2000	254	1	37	7	9	4	3	53
Principi et al, 2001	418			36			11	
Tsolia et al, 2004	75	3	7	35			3	31
Michelow et al, 2004	154		14	14			9	60

Modified from Ruuskanen GEM 7 Dublin 2009

## Question 1:

Are viruses important in the etiology of pediatric pneumonia?


1. Very rarely, < 10 % of cases
2. Yes, in > 90 % cases
3. Only in mild cases managed as outpatients
1. Only in those cases with no bacteria

# Virus detection in childhood pneumonia

	N	Total %	RSV %	Adeno %	Rhino %	Flu %	Parainfl %	Mixed %
Ruuskanen et al	50	60	30	10	10	2	8	34
Gendrel et al	104	29	10	4		4	6	8
Heiskanen et al	201	25	21	2		0	3	10
Wubbel et al	168	20	8	2		3	4	3
Juvén et al	254	62	29	7	24	4	10	30
Michelow et al	154	45	13	7	3	22	13	23
Tsolia et al	75	65	3	12	45	7	8	28
Cilla et al	338	67	20	3	14	7	11	
Hamamo et al	1700	43	9	2	15	7	7	15
Nascimento et al	184	60	15	3	21	9	17	23
Lahti et al	76	55	4	0	29	3	1	45
Wolf et al	1296	40	23	3.4		2.9	2.9	
Mathisen et al	629	30	14			7.2	10.3	
Total	5229	47	15	5	20	6	8	22

# Significance of viral-bacterial coinfections in pediatric pneumonia


# Etiology of pneumonia in hospitalized children



# Etiology of pneumonia in the community (EPIC)

## January 2010 to June 2012

- 2,638 children < 18 yr hospitalized pneumonia
- 2,222 confirmed x-ray
- 81% pathogen identified
- 66% virus
- 8% bacteria
- 7% virus and bacteria






**CHIRP**  
CHILDREN'S HOSPITALS'  
INITIATIVE FOR RESEARCH  
IN PNEUMONIA

- Prospective cohort study
- Community acquired pneumonia (CAP) diagnosed at 1 of 6 Ohio children's hospitals
- 2015-2018




# CHIRP Pneumonia Study in Ohio 2015-2018

442 children < 18 yr ; 283 (64%) pathogen identified




EV, Enterovirus; HRV, rhinovirus; AdV, Adenovirus;  
RSV, Respiratory syncytial virus; Flu, Influenza virus;  
HMpV, Human metapneumovirus

# Patients with viral pathogen detected (n=246)



EV, Enterovirus; HRV, Human rhinovirus; RSV, Respiratory syncytial virus; HMpV, Human metapneumovirus; Flu, Influenza virus; AdV, Adenovirus; PIV, Parainfluenza virus; CoV, Coronavirus

# Clinical Challenges for Diagnosing Pneumonia



## Question:

Can we differentiate viral vs bacterial pneumonia


## Question 2:

What about CX-ray: Does it help to with etiologic diagnosis?

1. Yes
2. No
3. Most of the times

Q3: Which pneumonia case has virus etiology:

1. Case A
2. Case B
3. Both
4. None




And the laboratory markers?


# BACTERIAL vs VIRAL PNEUMONIA

N=215	Bacterial %	Viral %
Alveolar infiltrates	71	29
Interstitial infiltrates	48	52
WBC $>15 \times 10^9/L$	63	37
ESR $>30 mm/h$	64	36
CRP $>40 mg/L$	70	30
CRP $>80 mg/L$	75	25

And this case, is it caused by virus or bacteria?




# Does the chest CT help?



# Bacterial detection in children with complicated pneumonia (2006-2010)


N=195 (68% pathogen identified)



\*\*Other includes:


- 2 Viridans group strep spp.
- 2 *Mycoplasma pneumoniae*
- 1 *H. influenzae*
- 1 *Eikenella* spp.

# Bacterial detection in pleural fluid



\*All other bacterial pathogens detected via culture

# Viruses detected in children with complicated pneumonia




# Virus detection associated with worse clinical outcomes in children with complicated pneumonia

	Virus + (n=22)	Virus – (n=44)	Odds Ratio [95% CI]	P-value
Length of hospitalization (days) <sup>1</sup>	12 [8.5-14]	8.5 [7-11]	N/A	<0.01
Respiratory support (days) <sup>1,2</sup>	4.5 [3-10]	3 [0-6]	N/A	0.04
Length of fever (days) <sup>1</sup>	8 [6-9]	5 [2-7]	N/A	<0.01
Surgical decortication <sup>3</sup>	8 (36%)	3 (7%)	7.8 [1.8-34]	<0.01
Necrotizing pneumonia <sup>3</sup>	17 (77%)	16 (36%)	6.0 [1.8-19]	<0.01
PICU admission <sup>3</sup>	11 (50%)	10 (23%)	3.4 [1.1-10]	<0.05
Need for intubation <sup>3</sup>	2 (9%)	4 (9%)	1.0 [0.2-5.9]	NS

<sup>1</sup>Median value [Interquartile range], <sup>2</sup>Respiratory support defined as supplemental oxygen, noninvasive ventilation, and intubation,

<sup>3</sup>Number of patients (%); \*Each case was matched with two controls for age, sex, race, bacterial pathogen, and viral testing

# Treatment of Pleural Effusion/Empyema



Pigtail catheter with  
instillation of tissue  
plasminogen activator (tPA)



Video-assisted thoracoscopic  
surgery

# Prospective randomized trial of VATS vs tube thoracostomy with fibrinolysis for empyema

Clinical outcome	VATS (N=18)	Fibrinolysis (N=18)	p
Post-Rx hospitalization (d)	$6.9 \pm 3.7$	$6.8 \pm 2.9$	0.96
Post-RX Oxygen support (d)	$2.3 \pm 1.7$	$2.3 \pm 2.1$	0.90
Post-RX time to afebrile (d)	$3.1 \pm 2.7$	$3.8 \pm 2.9$	0.46
Analgesia doses (no.)	$22.3 \pm 28.5$	$21.4 \pm 12$	0.90
Hospital charges	$\$11.7K \pm 2.9K$	$\$7.6K \pm 5.4K$	0.02

# Respiratory viruses and bacterial infections: Traditional perspective

Influenza



*S. pneumoniae, S. aureus*

RSV




very rare


Yes... but new evidence questions this viewpoint

# Recent Epidemiologic studies

# Viruses and *S. pneumoniae*: Epidemiological Link




# RSV, Flu and pneumococcus infections



# Virus–bacterial interactions: Potential strategies for intervention

# Management of pneumonia in patient with influenza



✓

Is it influenza?

Consider combination therapy

Oseltamivir

plus

Ampicillin or Ceftriaxone

Is it pneumonia?


# Recommended therapy for pediatric pneumonia in hospitalized children

- No risk factors and vaccinated: Ampicillin
- Not vaccinated +/- risk factors: Ceftriaxone
- Severe pneumonia + pleural disease: Ceftriaxone + Vancomycin (If MRSA common)
- Viral pneumonia: No antibiotics
- *Mycoplasma pneumoniae*: Azithromycin or Clarithromycin


# Factors Influencing Antibiotic Prescription at Discharge

Marzec et al Annual PAS Meeting 2018

# Results: Study Population (interim analysis)




# Results: October 2015 – March 2018




What about preventive strategies in  
pediatric pneumonia?


# Rates of invasive pneumococcal disease (IPD) among children < 5 yrs 1998-2015



# Pneumonia Hospitalizations Children < 2 years in Tennessee 1998-2013




# Long term association pneumococcal vaccination and rates of community acquired pneumonia in France




# New technologies in pneumonia research

# Blood is a source of transcriptional markers




# Transcriptomics: Clinical Application in Pneumonia

1 ml of blood




Gene Chips



RNA


Genome-wide  
Transcriptional Profiles

# Transcriptional profiles can discriminate viral vs bacterial vs coinfections in patients with pneumonia




# Bacterial vs Viral Pneumonia in Hospitalized Adults (10 genes)

## Training Set



	Sensitivity	Specificity
Procalcitonin	38% (18-62)	91% (76-98)
Classifier Genes	95% (77-100)	92% (77-98)

# Transcriptomics linking pathogenesis and clinical findings




Can we measure disease activity/severity  
using new genomics assays?




Molecular Distance to Health (MDTH)

# MDTH scores in children hospitalized with pneumonia (n=95, healthy controls=20)



Is this clinically relevant?

MDTH on admission correlates with days of hospitalization (LOS)



\*Spearman correlation

Wallihan et al, Frontiers Microbiology 2018

# Pneumonia in 2019

- Continues to represent a major challenge in children health
- Need improve etiologic diagnosis and patient stratification
- Simplified management strategies failed capture the complexity and resulted in overuse of antibiotics
- Application of new technologies: PCRs, gene profiles, imaging techniques
- Improved and targeted therapeutic approaches
- Ultimate goal: development and implementation of newer and improved vaccines; including respiratory viruses

MORE OF

Should Pneumonia be a Priority for Global Health?

Asuncion Mejías

Hasan Jafri

Carla Garcia

Susana Chavez-Bueno

Ana Gomez

Dora Estripeaut

Evelyn Torres

Juanita Lozano

Alejandro Jordan

Juan P. Torres

Sara Mertz

Emilio Flaño

Mario Marcon

Gail Arthur

Mike Lawson

Dan Cohen

Blerita Dimo

Eleonora Bunsow

Grace Wentzel

Samantha Sharpe

Debby Bogaert

Wouter de Steenhuijsen

# Acknowledgements



NIH: NIAID, NICHD, HRSA, OCHA  
CHIRP Investigators



NATIONWIDE CHILDREN'S  
*When your child needs a hospital, everything matters.*



THE OHIO STATE UNIVERSITY  
COLLEGE OF MEDICINE

Bennett Smith

Nicolas Suarez

Romain Banchereau

Damien Chaussabel

Virginia Pascual

Jacques Banchereau

Derek Blankenship

Santu Heinonen

Tuomas Hartti

Oli Ruuskanen

Phuong Nguyen

Casey Glaser

Pablo Sanchez

Monica Ardura

Jessica Estep

Santiago Lopez

Raquel Cao

M.C. Suarez

Nate Kuppermann

Prashant Mahajan

Victoria Best

Sara Merzec

Thanks!